Скачать с ютуб Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment в хорошем качестве

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment

CNM-Au8, an oral suspension of gold nanocrystals, was developed to restore neuronal health and function by increasing energy production and utilization. Although the treatment is shown in models to improve neuronal metabolic energy, it did not show benefit on primary or secondary endpoints in 2 trials, RESCUE-ALS and the HEALEY ALS Platform trial (NCT04297683; Regimen C). James Berry, MD, MPH, director of the Massachusetts General Hospital ALS Care Center, presented these findings of the survival analyses as an abstract at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27, in Boston, Massachusetts. Berry sat down with NeurologyLive® in an interview at AAN 2023 to provide an overview of the analyses and explain the significance of the findings for patients with ALS. He also talked about the differences in treatment responses observed in terms of the safety profile with the treatment. Additionally, he spoke about the next steps in research with CNM-Au8 including what should be studied further in future trials. (https://www.neurologylive.com/view/re...) View more AAN Content: https://www.neurologylive.com/confere...